Table 1.
Patient demographics and medical record.
| Age (years) | Surgical Procedure | Tumor Site | Histopathological Diagnosis | WHO Grade | Maximum Tumor Diameter (cm) | Extent of Resection | IDH1 Status | Tumor History | Previous Chemotherapy | Previous Radiotherapy | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 mg Cohort | |||||||||||
| Patient 1 | 55 | Awake craniotomy | left temporal | Glioblastoma | IV | 5.3 | STR | Wildtype | Primary | No | No |
| Patient 2 | 42 | Craniotomy | left frontal | Anaplastic oligodendroglioma | III | 5.0 | STR | Mutated | Recurrent | TMZ, CCNU and bevacizumab | Yes |
| Patient 3 | 67 | Craniotomy | left parietal | Glioblastoma | IV | 3.5 | NTR | Wildtype | Primary | No | No |
| Patient 4 | 72 | Craniotomy | left temporal | Glioblastoma | IV | 3.7 | GTR | Wildtype | Primary | No | No |
| Patient 5 | 62 | Craniotomy | left frontal | Glioblastoma | IV | 6.1 | STR | Wildtype | Recurrent | TMZ and bevacizumab | Yes |
| 100 mg Cohort | |||||||||||
| Patient 6 | 49 | Craniotomy | left frontal | Glioblastoma | IV | 1.3 | GTR | Wildtype | Primary | No | No |
| Patient 7 | 60 | Awake craniotomy | right frontal | Glioblastoma | IV | 4.4 | STR | Wildtype | Primary | No | No |
| Patient 8 | 67 | Craniotomy | left parietal | Glioblastoma | IV | 5.8 | STR | Wildtype | Primary | No | No |
| Patient 9 | 32 | Craniotomy | right temporal | Glioblastoma | IV | 2.8 | STR | Wildtype | Recurrent | TMZ and CP | Yes |
| Patient 10 | 70 | Awake craniotomy | left frontal | Glioblastoma | IV | 2.9 | NTR | Wildtype | Primary | No | No |
| Patient 11 | 36 | Craniotomy | right temporal | Glioblastoma | IV | 7.4 | STR | Wildtype | Recurrent | TMZ | Yes |
STR = subtotal resection, NTR = near total resection, GTR = gross total resection, TMZ = Temozolomide, CCNU = 1-[2-chloroethyl]3-cyclohexyl-1-nitrosurea, CP = cyclophosphamide.